Theriva™ biologics achieves target patient enrollment in the virage phase 2b trial of vcn-01 with gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer

- target of 92 evaluable patients (46 in each of the control and vcn-01 treatment arms) enrolled across 15 sites in spain and the usa within 21 months –

TOVX Ratings Summary

TOVX Quant Ranking